Armata Pharmaceuticals, Inc. (ARMP) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $192M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerTrading at $5.23, Armata Pharmaceuticals, Inc. (ARMP) is publicly traded in the U.S. valued at $192M. MoonshotScore: 16/100, Grade F — composite signals flag elevated risk. Educational signal, not a recommendation.
Price as of Sep 10, 2026 · Last analyzed: Sep 1, 2026ARMP stock analysis for 2026: Analysts have set a consensus price target of $15.00 for Armata Pharmaceuticals, Inc., suggesting 186.8% upside from the current price of $5.23. The AI MoonshotScore is 16/100, in the Weak band (below 45) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.
These figures come from statements filed 12 months ago — the most recent this company has published.
ARMP: 2/3 scored disciplines lean bearish. Dominant signal: Valuation weak.
How is this calculated? →Strongest side: Growth Durability (4/10, Weak). Weakest side: Valuation (1/10, Negative).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Armata Pharmaceuticals, Inc. Company Overview
Who Are ARMP's Competitors?
ARMP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.84% | $194M | — |
| NAGE Niagen Bioscience Inc | $3.04 | -0.49% | $242M | — |
| QTTB Q32 Bio Inc. | $10.77 | -3.37% | $320M | — |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | — |
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | — |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | 0.00% | $416M | — |
| CRMD CorMedix Inc. | $7.93 | -2.40% | $623M | — |
| MDXG MiMedx Group, Inc. | $4.60 | -1.71% | $671M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are the Key Risks for ARMP?
Financial-distress signal — its Altman Z-Score of -17.28 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
Research confidence
Broad, current evidence sits behind this analysis.
- ● Scored on 85% of our measures
- ● Price is current
- ● Latest filing 30 days ago
- ● Covered by analysts
Why 16?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.78 Return on equity (Business Quality)
- +0.15 Gross margin (Business Quality)
- +0.15 12-month price trend (Momentum)
What is holding it back
- -0.78 Return on assets (Business Quality)
- -0.78 Operating margin (Business Quality)
- -0.78 Net margin (Business Quality)
Risk penalties applied
- -1.89 Bankruptcy-risk score in the distress zone
- -2.00 Loss-making with negative retained earnings
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 14 |
| 2026-08-26 | 14 |
| 2026-08-29 | 14 |
| 2026-09-01 | 16 |
| 2026-09-04 | 15 |
| 2026-09-07 | 15 |
| 2026-09-10 | 16 |
What changed?
The grade moved from 14 to 16 (+2).
What moved it up or down:
- +7 Growth
- +3 Momentum
- +2 Business Quality
Held back by:
- -47 Financial Strength
- -3 Valuation
Over the same 18 days the stock moved +2.5%.
Insider Activity
Over the past six months, Armata Pharmaceuticals, Inc. insiders filed 2 SEC Form 4 transactions — 1 sales and 1 purchases. On net that is roughly 37K shares acquired (about $603K) — insiders putting money in tends to read as conviction.
Earnings Track Record
Armata Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 294.5% below estimates on average.
Financial Health
Armata Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -17.28 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Armata Pharmaceuticals, Inc. stands at 162.6%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -8.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.64 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -94.7%, the inverse of the P/E and a quick read on earnings relative to price.
Armata Pharmaceuticals, Inc. (ARMP) Valuation Context
Valued at $192M, ARMP is classified as a micro-cap stock. Analyst price targets span from $15.00 to $15.00, with a consensus of $15.00. At the current price of $5.23, that implies approximately 187% upside potential.
ARMP Revenue & Earnings Trend
In Q2 FY2026, ARMP generated $2.5M in top-line revenue, marking a sequential increase of 218.1%. The company recorded net income of $74.1M, with diluted EPS of $1.20. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap its sector company. Across the four most recent quarters, ARMP averaged $-1.53 in diluted EPS.
Company Profile
Armata Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Los Angeles, US. The company is led by CEO Deborah L. Birx. ARMP has traded publicly since 1994.
ARMP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $3M | $74M | $1.20 |
| Q1 FY2026 | $789,000 | -$115M | -$3.16 |
| Q4 FY2025 | $0 | -$124M | -$3.42 |
| Q3 FY2025 | $0 | -$27M | -$0.74 |
Q2 FY2026 · filed 12 Aug 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
ARMP Latest News
-
Armata Pharmaceuticals Announces Journal Of Molecular Biology Publication Detailing Structure Of Ar-KM Bacteriophage Targeting Pseudomonas Aeruginosa, Pathogen Addressed By Its AP-PA02 Program
benzinga · Sep 3, 2026
-
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
prnewswire.com · Sep 3, 2026
-
Bronchiectasis Market is Expected to Surge at a CAGR of 15% by 2036, Owing to the Launch of DPP1/CatC Inhibitors, Therapeutic Phage Cocktails, Nebulized Mucoactive Agents, and Other Novel Mechanisms | DelveInsight
Yahoo! Finance: ARMP News · Aug 13, 2026
-
Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate
benzinga · Aug 12, 2026
ARMP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ARMP.
Price Targets
Median: $15.00 (+186.8% from current price)
Source: FMP analyst consensus · as of Aug 25, 2026 · an estimate, not advice
ARMP MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. ARMP scores 16/100 (Grade F): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Latest News
Armata Pharmaceuticals Announces Journal Of Molecular Biology Publication Detailing Structure Of Ar-KM Bacteriophage Targeting Pseudomonas Aeruginosa, Pathogen Addressed By Its AP-PA02 Program
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
Bronchiectasis Market is Expected to Surge at a CAGR of 15% by 2036, Owing to the Launch of DPP1/CatC Inhibitors, Therapeutic Phage Cocktails, Nebulized Mucoactive Agents, and Other Novel Mechanisms | DelveInsight
Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate
Common Questions About ARMP
What does the AI Score mean for ARMP?
ARMP holds an AI Score of 16/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ARMP a good stock?
Stock Expert AI does not rate ARMP buy, sell or hold. Armata Pharmaceuticals, Inc. carries a MoonshotScore of 16/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the key factors to evaluate for ARMP?
Armata Pharmaceuticals, Inc. (ARMP) holds an AI score of 16/100 (low). Analysts target $15.00 (+187%). Not financial advice.
How frequently does ARMP data refresh on this page?
ARMP's price was last updated on Sep 10, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ARMP's recent stock price performance?
Armata Pharmaceuticals, Inc. (ARMP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ARMP overvalued or undervalued right now?
Armata Pharmaceuticals, Inc. (ARMP) is loss-making, so its trailing P/E is negative (-4.40x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Analysts target $15.00 (+187%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ARMP?
Yes, most major brokerages offer fractional shares of Armata Pharmaceuticals, Inc. (ARMP) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ARMP's earnings and financial reports?
Armata Pharmaceuticals, Inc. (ARMP) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ARMP earnings announcements.
What should investors new to ARMP understand first?
Armata Pharmaceuticals, Inc. (ARMP) is worth researching across volatility, fundamentals, and industry context. Its current AI score is 16/100. With a market cap of $192M, its size is a factor in volatility characteristics. Start with the Company Overview and MoonshotScore tabs for a structured introduction.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.